Type II spiral ganglion neurons (SGNs) are small caliber, unmyelinated afferents that extend dendritic arbors hundreds of microns along the cochlear spiral, contacting many outer hair cells (OHCs).
Identifying genes that are differentially expressed in type II versus type I afferent neurons would enable genetic manipulation to isolate the effects of type II afferents from those of the much larger population of type I afferents. Understanding the cellular actions of these selectively expressed genes also could shed light on the overall function of type II afferents. In previous work, tyrosine hydroxylase (Th), a marker for C-type low threshold mechanoreceptors in the somatosensory system, was shown to express in lateral olivocochlear (LOC) efferents and in type II but not type I afferent neurons, particularly in the apical cochlea (Vyas, Wu, Zimmerman, Fuchs, & Glowatzki, 2016) . This observation suggested a previously underappreciated heterogeneity among type II afferent neurons.
Indeed, in contrast to the much-diversified groups of ganglion neurons in other sensory systems such as vision and somatosensation (Abraira & Ginty, 2013; Basbaum, Bautista, Scherrer, & Julius, 2009; Sanes & Masland, 1992) , little is known beyond the type I and type II dichotomy for spiral ganglion neurons (SGNs) and activity differences among type I afferents. Therefore, the identification of additional genetic markers that could label type II afferent neurons in the basal cochlea is desirable. In view of the proposed role of type II afferents in detecting tissue damage, we continued to screen recombinant mouse lines labeling subpopulations of ganglion neurons in the somatosensory system, especially nociceptors, for their expression patterns in the cochlea.
One such gene, Calca, encoding for calcitonin gene-related peptide alpha (CGRPa), is expressed in a wide variety of neuronal and non-neuronal cell types, ranging from keratinocytes to primary afferent neurons and spinal motor neurons (Russell, King, Smillie, Kodji, & Brain, 1987) . CGRP is a potent vasodilator and mediates neuronal-immune system communication (Assas, Pennock, & Miyan, 2014) . CGRP is expressed specifically in small C and Ad neurons of dorsal root ganglia.
The release of CGRP from sensory terminals is thought to intensify pain sensation, in part through its induction of vasodilation and inflammation, but also by facilitating central transmission. CGRP's most infamous role is in migraine pathogenesis, where again, a combination of effects on vasodilation, inflammation, and central plasticity is thought to occur. CGRP has long been known to be expressed in cochlear efferent neurons (Kitajiri et al., 1985) . Its involvement in nociception makes the expression in type II cochlear afferents shown here particularly interesting in the context of acoustic trauma and associated "gain of function" pathologies such as hyperacusis.
| M A TE RI A L S A ND M E TH ODS
All procedures were in accordance with animal protocols approved by the Johns Hopkins University Animal Care and Use Committee. Mice of either sex were used in the experiments.
| Mouse lines
The CGRPa-EGFP [Tg(Calca-EGFP)FG104Gsat/Mmucd; RRID:
MMRRC_011187-UCD] mouse line, later referred to as CGRPa-EGFP
(GENSAT) mouse line in this manuscript, was generated by random insertion of a bacterial artificial chromosome containing regulatory sequences of the Calca gene followed by the EGFP reporter gene. This mouse line was generated by GENSAT (Gong et al., 2003) and obtained for the study here on a mixed background from Dr. David Ginty (Harvard University, MA). The CGRPa-EGFP (GENSAT) mouse line has been previously validated by its expression pattern in dorsal root ganglion (DRG) neurons (Bai et al., 2015) .
] mouse line was generated by insertion of the tamoxifen-inducible CreER gene into the Calca locus (Song et al., 2012 
| Immunofluorescence
The cochleae from postnatal day (P) 5 to 2-month-old mice were harvested, perfused through the round and oval windows, and fixed for 1 hr at room temperature (RT) with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) diluted in phosphate buffered saline (PBS). The whole mount neuroepithelia were microdissected in PBS. To better preserve and visualize the basal SGNs, some cochleae were decalcified in 0.2 M ethylenediaminetetracetic acid in PBS for 1-2 days before further processing. To achieve better tissue penetration for certain primary antibodies, an additional step involving incubation in 30%
sucrose, followed by a quick freeze at 2808C and thaw at 378C was performed. Dissected cochlear tissue was incubated for 1 hr at RT in a blocking and permeabilizing buffer (1x PBS with 10% normal donkey serum and 0.5% Triton X-100), before being incubated for 42 hr at RT with primary antibodies diluted in PBS containing 5% normal donkey serum, 0.25% Triton X-100, and 0.01% NaN 3 . Cochlear preparations were rinsed three times 5-10 min each in PBS before incubation with secondary antibodies (Table 1) , diluted 1,000-2,000 times in PBS containing 5% normal donkey serum and 0.25% Triton X-100 for 1-2 hr at RT. Preparations were again rinsed three times 10-30 min each in PBS before mounting on glass slides in FluorSave mounting medium (Calbiochem, San Diego, CA). All rinses were performed on a rocking table at RT.
| Antibody characterization
All primary antibodies used in this study are listed in Table 2 .
The rabbit anti-CGRP antibody used in this study labeled the wellestablished patterns of cochlear medial and lateral efferent terminals.
Its immunolabeling could be completely abolished by pre-adsorption with rat a-CGRP and partially eliminated with rat b-CGRP. Preadsorption with other types of neuropeptides resulted in no loss of immunostaining (manufacturer's datasheet). This antibody has been extensively used to label CGRP-positive DRG neurons and trigeminal sensory neurons (Hegarty, Tonsfeldt, Hermes, Helfand, & Aicher, 2010; Li & Ginty, 2014 (Du et al., 2001) . The goat anti-GFP antibody used in this study did not produce any labeling above background fluorescence on a wild-type cochlea, when this control tissue was processed together with cochlear tissues from the CGRPa-EGFP (GENSAT) mouse.
The rabbit anti-peripherin antibody has been validated for its use in immunohistochemistry. It stains a 57 kDa band specifically in western blot analysis and does not stain vimentin, GFAP, a-internexin or any of the neurofilament subunits (manufacturer's datasheet). It has been used for labeling the type II SGNs in multiple previous publications (Flores-Otero & Davis, 2011; Lang et al., 2011; McLean, Smith, Glowatzki, & Pyott, 2009 ).
The two antibodies against TuJ1 raised in rabbit and mouse respectively have both been validated for multiple applications including western blot analysis, immunohistochemistry, and immunofluorescence (manufacturer's datasheet). Both antibodies have been used extensively in previous publications, including some using cochlear samples (Davies, 2007; Flores-Otero & Davis, 2011) .
The specificity of the mouse anti-NKAa3 antibody has been verified by the vendor using western blot analysis of canine skeletal muscle extracts. Its specific labeling of type I SGNs in rat cochlea has been well characterized (McLean et al., 2009 ).
The rabbit anti-dsRed antibody can recognize DsRed-Express, The rabbit anti-myosin VI antibody and the mouse anti-myosin VIIa antibody are both used as hair cell markers and produced expected patterns (Korrapati, Roux, Glowatzki, & Doetzlhofer, 2013; Roux et al., 2009 ). The guinea pig anti-VAChT and the mouse anti-SV2 are used to label cochlear efferent terminals, which produced the well-established pattern in the Organ of Corti (Kong, Adelman, & Fuchs, 2008; Maison et al., 2016) .
| Image acquisition and quantification
Fluorescence images were acquired using a LSM 700 confocal microscope 
| Young adult CGRPa-EGFP (GENSAT) cochleas label type II, but not type I SGNs
The identity of labeled SGNs in 3-week to 2-month old CGRPa-EGFP Figure   4a ). However, CGRP-immunoreactivity in type II afferents was only observed in young (prior to hearing onset) mice, possibly due to decreased expression through development or to re-localization of CGRP to the axonal terminals in the cochlear nucleus. This perhaps explains why previous studies found CGRP immunolabeling only in cochlear efferents (Cabanillas & Luebke, 2002; Kitajiri et al., 1985; Maison et al., 2003; Safieddine & Eybalin, 2014; Sliwinska-Kowalska et al., 1989) . To test whether expression of Cgrpa in SGNs was specific to the CGRPa-EGFP (GENSAT) mouse, an additional mouse line was examined.
The knock-in CGRPa-EGFP (Zylka) mouse line showed GFP 1 SGNs in the base of a 1-week-old cochlea ( Figure 4b) . As in the CGRPa-EGFP FIG URE 2 Young adult CGRPa-EGFP (GENSAT) cochlea labels type II SGNs. The nonoverlapping labeling with type I SGN markers TuJ1 (b3 tubulin) (a-c) and NKAa3 (a3 Na 1 /K 1 ATPase) (e, f) suggests that the young adult CGRPa-EGFP (GENSAT) mouse cochlea labels type II SGNs. In (e), two type I SGNs were circled to help visualize the plasma membrane labeling by NKAa3 antibody. A selective region of OHCs demonstrates the typical type II fiber endings labeled in CGRPa-EGFP (GENSAT) mouse cochlea (g). Mouse age: 3-4 week old for (a-c), P30 for (e-g). Scale bar: 50 mm in (a-c), and 10 mm in (e-g) (GENSAT) mouse, these GFP 1 SGNs showed partial overlap with peripherin-positive SGNs (Figure 4c-e) , confirming the type II identity in a subset of GFP 1 SGNs. However, reporter expression was not as robust in this mouse line, and labeling was unconvincing in older cochleas, again suggesting that Cgrpa expression may decline with maturation.
| Cgrpa and Th showed opposing gene expression gradients in SGNs along the cochlear spiral
The expression of Cgrpa along the cochlear spiral was quantified by counting labeled somata in the spiral ganglion of CGRPa-EGFP (GEN-SAT) mouse cochleas ( Figure 5 ). Each cochlear whole mount was divided into 10 equal segments in ImageJ (Figure 5b ) and cell counts were recorded per segment. As seen in the sample cochlea (P30; Figure   5c ) and in the averaged data (Figure 5d ), GFP 1 SGNs were less common in apical segments of the cochlea. This rising gradient toward the cochlear base was present both before and after the onset of hearing, although the total number of GFP 1 SGNs was greater in the prehearing postnatal cochlea (Figure 5d ). Variability in the amplitude of the gradient was also observed among individual cochleas.
Previous work has shown TH as a biomarker for type II afferent neurons, particularly in the cochlear apex . To compare with Cgrpa cochlear expression patterns, the numbers of TH 1 SGNs along the cochlea were quantified using the same method. TH In contrast to the expression pattern of Cgrpa, TH 1 SGNs were more numerous in apical segments ( Figure 6 ). This declining gradient from apex to base was observed with both labeling strategies, though the mouse line usually labels fewer SGNs, possibly due to inadequate CGRPa-EGFP (GENSAT) mouse cochleas were obtained and examined.
A fraction of SGNs in mid-regions of the cochlea were positive for both GFP and tdTomato immunolabel (detected by an antibody against dsRed), but not for that against TuJ1 (marking type I SGNs), suggesting these are type II SGNs that co-express Cgrpa and Th (Figure 8 ).
| D I SCUSSION
In the present study, the gene Calca/Cgrpa is shown to be expressed in type II versus type I afferent neurons after hearing onset. Furthermore, Calca/Cgrpa drives reporter expression preferentially in "higher frequency" type II SGNs nearer the cochlear base, producing a spatial expression gradient complementary to that of Th, which is expressed preferentially in apical ("lower frequency") type II SGNs.
| Mouse genetic tools to selectively target type II afferent fibers
Since the earliest descriptions of cochlear innervation, the unusual innervation pattern of type II afferents has attracted attention and conjecture (De N o, 1976) . Early proposals took the logical view that the extensive connectivity of "external spiral fibers" (spironeuren) with
OHCs on the more-mobile portion of the basilar membrane implied greater acoustic sensitivity (Davis, 1961; von B ek esy, 1987) , or that they served as sensors to modulate the set-point of OHC activity, akin to the role of muscle spindle afferents (Kim, 1984) . While functional studies remain hampered by the scarcity and small, unmyelinated processes of type II afferents, heroic efforts provided one anatomicallyconfirmed recording in vivo (Robertson, 1984) , and characterization of several more identified by their much slower antidromic conduction velocity (Brown, 1994; Robertson et al., 1984) . In contrast to those earlier expectations of greater acoustic sensitivity, none of these afferents had spontaneous activity, and all were insensitive or unresponsive to sound (of 28 fibers reported in these publications, only 1 responded to broadband noise at 80 dB SPL). This acoustic insensitivity and morphological similarity to somatic C-fibers led to speculation that type II afferents may signal tissue trauma (Tonndorf, 1987) rather than sound per se, as has been supported by experimental findings in vivo (Flores et al., 2015) and ex vivo Weisz, Glowatzki, & Fuchs, 2016; Weisz et al., 2009 ).
Further exploration of type II function will benefit from genetic tools that enable selective manipulations for morphological, physiological, and behavioral analyses. Type II afferents are preferentially labeled by antibodies to the intermediate filament protein peripherin (Hafidi, 1998; Huang, Thorne, Housley, & Montgomery, 2007) prompting its use as a genetic tool, but with mixed results (Froud et al., 2015; FIG URE 4 Cgrpa is expressed in type II afferent neurons of 1-week-old mice. CGRP antibody stained the three outer spiral bundles in the OHC region in P6 C57BL/6J wild-type (WT) mouse cochlea (a), suggesting that the CGRP is expressed in type II fibers. A knock-in CGRPa-EGFP (Zylka) mouse line also showed labeling of SGNs in the base at P6-8 age (asterisks in b). These SGNs also showed partially overlapping labeling with Prph (arrows in c-e). Scale bar: 20 mm in (a-b), and 10 mm in (c-e)
|
The Journal of Comparative Neurology Maison et al., 2003) , possibly due to more widespread expression during development (Hafidi et al., 1993) . Additional type II-specific genes can be identified by gene-profiling strategies, or by survey of selective biomarkers found in analogous cell types, the strategy adopted here.
Th and Cgrpa, two genes expressed in somatic C-fibers, were found to be expressed selectively in type II SGNs after hearing onset, suggesting their use as genetic tools. However, caution should be taken to avoid confounding effects due to the expression of these genes in other neuronal types that could influence cochlear function. Cgrpa is expressed in medial and lateral efferents (Cabanillas & Luebke, 2002; Kitajiri et al., 1985; Maison et al., 2003; Safieddine & Eybalin, 2014; Sliwinska-Kowalska et al., 1989) . Th is also expressed in lateral efferents and sympathetic fibers (Darrow, Simons, Dodds, & Liberman, 2006) . Because the cell bodies of these other neuron types are located outside of the cochlea, a combination of mouse genetic tools with local viral injection may help to affect type II afferent fibers selectively. expressed in all SGNs during development, could be a marker for type II SGNs in the adult cochlea (Nishimura et al., 2017) . However, it remains to be determined whether Gata3 labels the entire type II neuron population.
| Genes expressed in small diameter DRG neurons are found in type II afferent neurons
Small diameter, unmyelinated C-fibers encode a variety of noxious sensations and can be subdivided by molecular markers (Green & Dong, 2016; Le Pichon & Chesler, 2014) . TH is expressed in C-fibers that normally convey innocuous mechanical sensations, but could released by trigeminal nociceptive neurons has been shown to upregulate P2X 3 expression in these neurons; a similar mechanism could be adopted by type II afferent fibers (Fabbretti et al., 2006 Cochlear afferents carry information to the cochlear nucleus where the perceived sound features, including pitch, loudness, timbre, duration, and location, begin to be directed to separate central circuits. Given their relative insensitivity to sound, type II afferent neurons are unlikely to be involved in this processing. Rather, damaging levels of sound increase activity-dependent c-Fos labeling in the granule cell domain of the cochlear nucleus complex (Flores et al., 2015) , the locus of type II synaptic contacts (Benson & Brown, 2004; Brown & Ledwith, 1990) .
Given the differential expression patterns of Th and Cgrpa reported here, it will be of interest to determine the central projections of these differentiated type II afferent neurons.
The present work describes a spatial gene expression gradient of (Nishimura et al., 2017) . Previous work has shown that only a subset of TH-positive type II afferent neurons were peripherin-positive . Maison et al. (2003) 
